Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation

Heinz Wiendl; Peter A. Calabresi; Sven G. Meuth

doi:10.1212/WNL.0000000000004969

Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation

Heinz Wiendl, Peter A. Calabresi, Sven G. Meuth

School of Medicine

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	309-311
Number of pages	3
Journal	Neurology
Volume	90
Issue number	7
DOIs	https://doi.org/10.1212/WNL.0000000000004969
State	Published - Feb 13 2018

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0000000000004969

Cite this

@article{3400d80379694846bf2be3bec278c7ab,

title = "Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation",

author = "Heinz Wiendl and Calabresi, {Peter A.} and Meuth, {Sven G.}",

note = "Funding Information: Heinz Wiendl receives honoraria for acting as a member of Scientific Advisory Boards and as consultant for Biogen, Evgen, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, and Sanofi-Genzyme, as well as speaker honoraria and travel support from Alexion, Biogen, Cog-nomed, F. Hoffmann-La Roche Ltd., Gemeinn{\"u}tzige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Sanofi-Genzyme, TEVA, and WebMD Global. Prof. Wiendl acts as a paid consultant for AbbVie, Actelion, Biogen, IGES, Novartis, Roche, Sanofi-Genzyme, and the Swiss Multiple Sclerosis Society. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Else Kr{\"o}ner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children{\textquoteright}s Foundation, Biogen GmbH, GlaxoSmithKline GmbH, Roche Pharma AG, and Sanofi-Genzyme. Peter Calabresi has received consulting fees from Biogen Idec and DiSARM Therapeutics. He is PI on grants to Johns Hopkins University from Annexon, MedImmune, Genzyme, Novartis, and Biogen. Sven G. Meuth has received honoraria for lecturing, travel expenses for attending meetings, and financial research support from Almirall, Bayer Health Care, Biogen, Diamed, Genzyme, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, and Teva. Go to Neurology. org/N for full disclosures. Funding Information: H.W.{\textquoteright}s and S.G.M.{\textquoteright}s work is supported by the German Research Foundation (DFG) and the Ministry of Education and Research (BMBF, the German Competence Network MK, KKNMS).",

year = "2018",

month = feb,

day = "13",

doi = "10.1212/WNL.0000000000004969",

language = "English (US)",

volume = "90",

pages = "309--311",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - Defining response profiles after alemtuzumab

T2 - Rare paradoxical disease exacerbation

AU - Wiendl, Heinz

AU - Calabresi, Peter A.

AU - Meuth, Sven G.

N1 - Funding Information: Heinz Wiendl receives honoraria for acting as a member of Scientific Advisory Boards and as consultant for Biogen, Evgen, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, and Sanofi-Genzyme, as well as speaker honoraria and travel support from Alexion, Biogen, Cog-nomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Sanofi-Genzyme, TEVA, and WebMD Global. Prof. Wiendl acts as a paid consultant for AbbVie, Actelion, Biogen, IGES, Novartis, Roche, Sanofi-Genzyme, and the Swiss Multiple Sclerosis Society. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children’s Foundation, Biogen GmbH, GlaxoSmithKline GmbH, Roche Pharma AG, and Sanofi-Genzyme. Peter Calabresi has received consulting fees from Biogen Idec and DiSARM Therapeutics. He is PI on grants to Johns Hopkins University from Annexon, MedImmune, Genzyme, Novartis, and Biogen. Sven G. Meuth has received honoraria for lecturing, travel expenses for attending meetings, and financial research support from Almirall, Bayer Health Care, Biogen, Diamed, Genzyme, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, and Teva. Go to Neurology. org/N for full disclosures. Funding Information: H.W.’s and S.G.M.’s work is supported by the German Research Foundation (DFG) and the Ministry of Education and Research (BMBF, the German Competence Network MK, KKNMS).

PY - 2018/2/13

Y1 - 2018/2/13

UR - http://www.scopus.com/inward/record.url?scp=85050015295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050015295&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000004969

DO - 10.1212/WNL.0000000000004969

M3 - Article

C2 - 29352097

AN - SCOPUS:85050015295

SN - 0028-3878

VL - 90

SP - 309

EP - 311

JO - Neurology

JF - Neurology

IS - 7

ER -

Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this